Catalog name Description price
R-C-539 TCS PIM-1 4a CAS: 438190-29-5 TCS PIM-1 4a is a selective and ATP-competitive Pim kinase inhibitor(IC50 values=24 and 100 nM for Pim-1 and Pim-2,respectively). price>
R-C-551 (NSC 42834)JAK2 Inhibitor V Z3 CAS :195371-52-9 NSC 42834(JAK2 Inhibitor V,Z3) is a novel specific inhibitor of Jak2,inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner. price>
R-C-574 SMI-4a cas:327033-36-3 SIM-4a is a Pim kinase inhibitor that blocks mTORC1 activity via activation of AMPK.Mostly potent to Pim-2,does not significantly inhibit any other serine/threonine-or tyrosine-kinases. price>
R-C-595 TG101348 cas:936091-26-8 Fedratinib(SAR302503,TG101348)is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays,35-and 334-fold more selective for JAK2 versus JAK1 and JAK3.Fedratinib also inhibits FMS-like tyrosine kinase 3(FLT3)and RET (c-RET)with IC50 of 15 nM and 48 nM,respectively. Fedratinib has potential antineoplastic activity.Fedratinib inhibits proliferation and induces apoptosis. price>
R-C-616 Icotinib cas:610798-31-7 Icotinib(BPI-2009H)is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR,EGFR(L858R),EGFR(L861Q),EGFR(T790M) and EGFR(T790M,L858R). price>
R-C-622 AT9283 cas:896466-04-9 AT9283 inhibits aurora kinase A and B and targets other tyrosine and serine/threonine kinases associated with myeloid cell proliferation. price>
R-C-625 CP690550 cas:540737-29-9 Tofacitinib citrate(CP-690550 citrate)is a novel inhibitor of JAK with IC50 of 1 nM,20 nM and 112 nM against JAK3,JAK2,and JAK1,respectively.Tofacitinib citrate has anti-infection activity. price>
R-C-659 XL019 CAS:945755-56-6 XL019 is a potent,orally active,and selective JAK2 inhibitor,with IC50s of 2.2,134.3,and 214.2 nM for JAK2,JAK1 and JAK3,respectively.XL019 shows 50-fold or greater selectivity for JAK2,versus a panel of over 100 serine/threonine and tyrosine kinases,including other members of the JAK family.XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2. price>
R-C-675 SB1518(Pacritinib) cas:937272-79-2 Pacritinib,also known as SB1518,is an orally bioavailable inhibitor of Janus kinase 2(JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity.Pacritinib competes with JAK2 for ATP binding,which may result in inhibition of JAK2 activation,inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. price>
R-C-717 CYT387(Momelotinib) CAS:1056634-68-4 Momelotinib(CYT387)is an ATP-competitive inhibitor of JAK1/JAK2 with IC50a of 11 nM and 18 nM,respectively.CYT387 shows much less activity against JAK3. price>